Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

Fortner, Renée T; Boeing, Heiner; Merritt, Melissa A; Navarro, Carmen; Tumino, Rosario; Johnson, Theron S; Weiderpass, Elisabete; Idahl, Annika; Vitonis, Allison F; Terry, Kathryn L; Nodin, Björn; Kaaks, Rudolf; Hüsing, Anika; Fashemi, Titilayo; Overvad, Kim; Papatesta, Eleni-Maria; Tjønneland, Anne; Quirós, J Ramón; Sacerdote, Carlotta; Onland-Moret, N Charlotte; Sánchez, Maria-Jose; Fichorova, Raina N; Kvaskoff, Marina; Duell, Eric J; Lundin, Eva; Khaw, Kay-Tee; Schock, Helena; Gunter, Marc; Riboli, Elio; Hansen, Louise; Dossus, Laure; Mattiello, Amalia; Peeters, Petra H; Yamamoto, Hidemi S; Larrañaga, Nerea; Le Cornet, Charlotte; Ardanaz, Eva; Palli, Domenico; La Vecchia, Carlo; Travis, Ruth C; Boutron-Ruault, Marie-Christine; Severi, Gianluca; Johansson, Mattias; Bueno-de-Mesquita, H B As; Jirström, Karin; Trichopoulou, Antonia; Cramer, Daniel W; Sieri, Sabina

doi:10.1002/ijc.31164

Journal Article

DKFZ-2018-00158

Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

Fortner, R. T. (First author)DKFZ* ; Schock, H.DKFZ* ; Le Cornet, C.DKFZ* ; Hüsing, A.DKFZ* ; Vitonis, A. F. ; Johnson, T. S. ; Fichorova, R. N. ; Fashemi, T. ; Yamamoto, H. S. ; Tjønneland, A. ; Hansen, L. ; Overvad, K. ; Boutron-Ruault, M.-C. ; Kvaskoff, M. ; Severi, G. ; Boeing, H. ; Trichopoulou, A. ; Papatesta, E.-M. ; La Vecchia, C. ; Palli, D. ; Sieri, S. ; Tumino, R. ; Sacerdote, C. ; Mattiello, A. ; Onland-Moret, N. C. ; Peeters, P. H. ; Bueno-de-Mesquita, H. B. A. ; Weiderpass, E. ; Quirós, J. R. ; Duell, E. J. ; Sánchez, M.-J. ; Navarro, C. ; Ardanaz, E. ; Larrañaga, N. ; Nodin, B. ; Jirström, K. ; Idahl, A. ; Lundin, E. ; Khaw, K.-T. ; Travis, R. C. ; Gunter, M. ; Johansson, M. ; Dossus, L. ; Merritt, M. A. ; Riboli, E. ; Terry, K. L. ; Cramer, D. W. ; Kaaks, R. (Last author)DKFZ*

2018
Wiley-Liss Bognor Regis

International journal of cancer 142(7), 1355 - 1360 (2018) [10.1002/ijc.31164]

This record in other databases:

Please use a persistent id in citations: doi:10.1002/ijc.31164

Abstract: CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.

Classification: